Clostridioides difficile Health-related Quality-of-Life Questionnaire (Cdiff32)
In 2016 we developed and validated a quality-of-life survey specifically for patients with C. difficile infection. The Cdiff32 is an instrument containing 32 items related to the physical, mental, and social health of CDI patients.
The Cdiff32 is now publicly available in six languages below.
Suggested citation(s):
Questionnaire: Garey, KW. Clostridioides difficile Health-related Quality-of-Life Questionnaire (Cdiff32). Houston, TX: The Garey Lab, University of Houston College of Pharmacy. https://www.thegareylab.com/c-diff-32-questionnaire.
Development and validation: Garey KW, Aitken SL, Gschwind L, et al. Development and validation of a Clostridium difficile health-related quality-of-life questionnaire. J Clin Gastroenterol 2016; 50: 631–37.
Publications using the Cdiff32:
Kao D, Wong K, Franz R, Cochrane K, Sherriff K, Chui L, Lloyd C, Roach B, Bai AD, Petrof EO, Allen-Vercoe E. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial. Lancet Gastroenterol Hepatol. 2021 Apr;6(4):282-291. doi: 10.1016/S2468-1253(21)00007-8. Epub 2021 Feb 23. PMID: 33631102.
Han Z, Lapin B, Garey KW, Donskey CJ, Deshpande A. Impact of Clostridioides difficile infection on patient-reported quality of life. Infect Control Hosp Epidemiol. 2021 Oct 7:1-6. doi: 10.1017/ice.2021.413. Epub ahead of print. PMID: 34615561.